A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 in Asian Patients With Advanced Solid Malignancies and Asian Patients With Child-Pugh A to B7 Advanced Hepatocellular Carcinoma (HCC) in the Escalation Phase, Estimated Glomerular Filtration Rate(EGFR) or ROS Mutant NSCLC and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour With Biopsy Available in the Expansion Phase.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2013
At a glance
- Drugs AZD 1480 (Primary)
- Indications Cancer metastases; Gastric cancer; Liver cancer; Solid tumours
- Focus Adverse reactions
- 01 Dec 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 09 Oct 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 26 Jul 2012 Official title amended, primary endpoint and additional lead trial investigators added as reported by ClinicalTrials.gov.